Credit Suisse Upgrades Salix (Nasdaq: SLXP) to Outperform
More News related to SLXP
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Salix Pharmaceuticals to Host Analyst Day on November 18
- Salix Pharmaceuticals to Present at Credit Suisse Conference
- Salix Pharma (SLXP) Announces the Issuance of Two Patents Related to Rifaximin
- Salix Pharmaceuticals Secures Additional Intellecutual Property Relating to Rifaximin
More News related to Upgrades
- Lazard Capital Downgrades Abiomed (ABMD) to Hold
- Dougherty & Co Downgrades NightHawk Radiology (NHWK) to Neutral
- Ardour Capital Downgrades Ormat Technologies (ORA) to Hold
- Capital One Southcoast Downgrades Stone Energy (SGY) to Neutral
- Barclays Downgrades Gap, Inc. (GPS) to Equalweight
Credit Suisse upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Neutral to Outperform.
Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs used in the treatment of gastrointestinal disorders in the United States.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
